Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Neuroendocrine Cancer Clinical Trial

Official title:

Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02318784
• Other study ID #: SCRI GI 195
• Status: Completed
• Phase: Phase 2
• Start date: July 15, 2015
• Est. completion date: May 15, 2021

Study information

• Verified date: June 2022
• Source: SCRI Development Innovations, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.

Description:

Neuroendocrine malignancies such as pancreatic neuroendocrine tumors (PNETs) and gastrointestinal (GI) carcinoids, are generally rare but their incidences are increasing. In vitro and in vivo studies have shown that proteasome inhibitors have activity against a variety of tumor types. Carfilzomib (Kyprolis®) is an irreversible proteasome inhibitor with a favorable safety profile that has been studied in a variety of hematologic and solid tumors. Carfilzomib received accelerated approval from the U.S. FDA in 2012, based on a favorable response rate, for the treatment of patients with multiple myeloma who received at least two prior therapies, and demonstrated disease progression within 60 days of completing the last therapy. In this multi-center study, the investigators propose to evaluate carfilzomib for the treatment of patients with advanced neuroendocrine cancers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: May 15, 2021
• Est. primary completion date: May 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adults with biopsy-proven advanced, unresectable or metastatic, well-to-moderately differentiated (or low grade) neuroendocrine carcinoma, including typical carcinoid, pancreatic islet cell and other well-to-moderately differentiated neuroendocrine carcinomas.

2. Measurable disease per Response Evaluation Criteria in Solid Tumors RECIST v 1.1 criteria.

3. Patients currently receiving or previously treated with single agent sandostatin LAR® are eligible. However, this is not a mandatory criterion to be included in the study.

4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.

5. Adequate hematologic, renal, and hepatic function.

6. Predicted life expectancy > 12 weeks.

Exclusion Criteria:

1. Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, globlet cell carcinoid, atypical carcinoid, anaplastic carcinoid, pulmonary neuroendocrine and small cell carcinoma are not eligible.

2. Patients who had radiation therapy, hormonal therapy, biologic therapy, investigational agents, or chemotherapy for cancer within 21 days or 5 half-lives of any chemotherapy or biologic/targeted agent, whichever is longer, prior to first treatment day of the study.

3. Concurrent severe, intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would impair the ability of the patient to receive protocol treatment.

4. Major surgical procedures =28 days of beginning study drug, or minor surgical procedures =7 days. No waiting required following port-a-cath placement.

5. Previously untreated brain metastases. Patients who have received radiation or surgery for brain metastases are eligible if therapy was completed at least 2 weeks prior to study entry and there is no evidence of central nervous system disease progression, mild neurologic symptoms, and no requirement for chronic corticosteroid therapy.

6. Known diagnosis of human immunodeficiency virus, hepatitis B or hepatitis C.

Related Conditions & MeSH terms

• Carcinoma, Neuroendocrine
• Neuroendocrine Cancer

Intervention

Drug:
• Carfilzomib

Locations

Country	Name	City	State
United States	Oncology Hematology Care, INC.	Cincinnati	Ohio
United States	Rocky Mountain Cancer Center	Denver	Colorado
United States	Florida Cancer Specialists	Fort Myers	Florida
United States	Center for Cancer and Blood Disorders	Fort Worth	Texas
United States	Ingalls Cancer Research Center	Harvey	Illinois
United States	Research Medical Center	Kansas City	Missouri
United States	Tennessee Oncology PLLC	Nashville	Tennessee
United States	Florida Hospital Cancer Institute	Orlando	Florida
United States	Florida Cancer Specialists - North	Saint Petersburg	Florida
United States	Spartanburg Regional Medical Center/Gibbs Cancer Center	Spartanburg	South Carolina

Sponsors (2)

Lead Sponsor	Collaborator
SCRI Development Innovations, LLC	Amgen

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR)	Percentage of participants with confirmed complete response (CR) or partial response (PR) (i.e. 2 CRs or PRs at least 4 weeks apart) to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) CR=disappearance of all target lesions. PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.	every 3 cycles (1 cycle= 28 days) until treatment discontinuation up to 4 years
Secondary	Disease Control Rate (DCR)	Percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) (= 6 cycles) according to RECIST v1.1 criteria. Complete Response is defined per RECIST as the disappearance of all target/non-target lesions and normalization of tumor markers. Partial Response is defined per RECIST as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Stable disease is defined per RECIST as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest (nadir) sum LD since the treatment started.	every 3 cycles (1 cycle= 28 days) until treatment discontinuation up to 4 years
Secondary	Progression Free Survival (PFS)	Measured from Day 1 of study drug administration to disease progression as defined by RECIST v1.1, or death on the study. Progressive Disease (PD): At least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or unequivocal progression of non-target lesions or the appearance of one or more new lesions. Patients who did not have disease progression or death documented were censored on the date of the last visit with adequate assessment.	up to 4 years
Secondary	Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability	The number of treatment-emergent adverse events will be graded utilizing the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03	From the day of the first dose to 30 days after the last dose of study medication, up to 4 years